Neurocrine Biosciences revenue and financials

NBIX · NASDAQ · USD

Compare Neurocrine Biosciences
$165.92Change from previous close: +0.37%Absolute change: +$0.61

Close · November 17, 2026

In the fiscal year ended December 2025, Neurocrine Biosciences reported revenue of $2.86B (+21.45% year over year). Net income was $478.6M, a net margin of 16.7%.

Annual revenue · 2025: $2.86B
  1. $15M2016
  2. $161.63M2017
  3. $451.2M2018
  4. $788.1M2019
  5. $1.05B2020
  6. $1.13B2021
  7. $1.49B2022
  8. $1.89B2023
  9. $2.36B2024
  10. $2.86B2025

Fiscal year ending in December. Sources and method on the page How we analyse stocks.

At a glance

Revenue growth
+21.45%
2025 vs 2024
Net income growth
+40.23%
2025 vs 2024
Net margin
16.7%
2024: 14.5%

How Neurocrine Biosciences is changing

Calculated from the annual statements; each fiscal year is labelled with the year it ends.

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Annual
Item2025202420232022202120202019201820172016
Total revenue2,8612,3551,8871,4891,1341,04678845116215.0
Cost of revenue52.134.039.723.214.310.12074.91.30.0
Gross profit1,7931,5901,2821,00279176158129168.5-20.9
Selling, general and administrative1,15699388875358343335424917068.1
Research and development1,016731565464———16112294.3
Operating income61957125124910316372.336.8-131-147
EBIT63759739524920832822741.6-101-147
EBITDA66762441626521933623445.6-99.0-146
Interest expense—1274.67.125.832.832.030.519.50.0
Pre-tax income70548633221410110746.521.8-143-141
Income tax22714582.459.411.8-3019.50.70.00.0
Net income47934125015589.640737.021.1-143-141
Net income to common shareholders47934125015589.640737.021.1-143-141
Basic EPS4.813.402.561.610.954.380.400.23-1.62-1.63
Diluted EPS4.673.292.471.560.924.160.390.22-1.62-1.63
Average shares (basic)99.510097.795.894.693.191.690.288.186.7
Average shares (diluted)10310410198.997.997.895.795.488.186.7

Companies in the group: same industry, similar size